AndreaBozzo/ceres-open-data-index huggingface dataset:
Patent AT-E400658-T1: [Translated] ENTERIC TRANSMITTED NON-A/NON-B HEPATITIS VIRUS AGENT AND CHARACTERISTIC EPITOPES OF THE SAME

Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent (HEV) are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in individuals infected with the viral hepatitis agent. This protein is useful in a diagnostic method for detecting infection by the enterically transmitted agent. Specific epitopes have been identified that are reactive with sera of individual infected with different strains of HEV. Also disclosed are DNA probes derived from a cloned sequence of the viral agent. These probes are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, by using probe-specific amplification of virus-derived DNA fragments.
Compound 525180: Pentapropylene glydol, diacetate

Chemical compound data from PubChem database. IUPAC Name: 2-[2-[2-[2-(2-acetyloxypropoxy)propoxy]propoxy]propoxy]propyl acetate. Molecular Formula: C19H36O8. Molecular Weight: 392.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Obesity among children and adolescents aged 2–19 years, by selected characteristics: United States

Data on obesity among children and adolescents aged 2-19 years by selected population characteristics. Please refer to the PDF or Excel version of this table in the HUS 2019 Data Finder (https://www.cdc.gov/nchs/hus/contents2019.htm) for critical information about measures, definitions, and changes over time. 

SOURCE: NCHS, National Health and Nutrition Examination Survey. For more information on the National Health and Nutrition Examination Survey, see the corresponding Appendix entry at https://www.cdc.gov/nchs/data/hus/hus19-appendix-508.pdf.
HHS IDs

<b>After May 3, 2024, this dataset and webpage will no longer be updated because hospitals are no longer required to report data on COVID-19 hospital admissions, and hospital capacity and occupancy data, to HHS through CDC’s National Healthcare Safety Network. Data voluntarily reported to NHSN after May 1, 2024, will be available starting May 10, 2024, at <a href="https://covid.cdc.gov/covid-data-tracker/#hospitalizations-landing">COVID Data Tracker Hospitalizations</a>.</b>
<br><br>
This file helps define the HHS_ID column that is published in both the
<br><br>
'COVID-19 Reported Patient Impact and Hospital Capacity by Facility' found here: https://healthdata.gov/Hospital/COVID-19-Reported-Patient-Impact-and-Hospital-Capa/anag-cw7u
<br><br>
COVID-19 Reported Patient Impact and 'Hospital Capacity by Facility -- RAW' found here: https://healthdata.gov/Hospital/COVID-19-Reported-Patient-Impact-and-Hospital-Capa/uqq2-txqb
<br><br>
As a part of an effort to improve the granularity of spatial data, unique identifiers (named “HHS IDs” in the datasets) have been assigned to each individual facility. These unique identifiers are provided so data users can reference each individual “brick and mortar” facility that is reporting data to HHS, even in cases when multiple facilities report under the same CMS Certification Number (CCN). Additional datasets and further details related to HHS IDs will be released at a later date.
<br><br>
With this file, you can associate the reporting facility with its physical location(s).
<br><br>
On October 8, 2021, this file will now include the HHS IDs for Psychiatric, Rehabilitation and Behavioral hospitals, as well as Ambulatory Surgical Centers and Free Standing Emergency departments wherever these institutions are reporting under https://www.hhs.gov/sites/default/files/covid-19-faqs-hospitals-hospital-laboratory-acute-care-facility-data-reporting.pdf
<br><br>
Starting on January 6, 2023, this dataset will no longer be posted on weekends.
Levetiracetam

Levetiracetam is an injectable anticonvulsant medication used to treat seizures by reducing abnormal electrical activity in the brain. Manufactured by Sagent Pharmaceuticals, it's available as a 500 mg/5 mL (100 mg/mL) intravenous solution in vials. This generic version (ANDA091627) is prescribed for adults and children with epilepsy. This information was generated using AI and is provided for informational and research purposes only.
2011 CMHS Uniform Reporting System (URS) Output Tables for Massachusetts

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2011. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 529962: 3,5,5-Trimethylhex-2-enal

Chemical compound data from PubChem database. IUPAC Name: 3,5,5-trimethylhex-2-enal. Molecular Formula: C9H16O. Molecular Weight: 140.22. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Lateral gene transfer and parallel evolution in the history of glutathione biosynthesis genes

Background
          Glutathione is found primarily in eukaryotes and in Gram-negative bacteria. It has been proposed that eukaryotes acquired the genes for glutathione biosynthesis from the alpha-proteobacterial progenitor of mitochondria. To evaluate this, we have used bioinformatics to analyze sequences of the biosynthetic enzymes γ-glutamylcysteine ligase and glutathione synthetase.
        
        
          Results
          γ-Glutamylcysteine ligase sequences fall into three groups: sequences primarily from gamma-proteobacteria; sequences from non-plant eukaryotes; and sequences primarily from alpha-proteobacteria and plants. Although pairwise sequence identities between groups are insignificant, conserved sequence motifs are found, suggesting that the proteins are distantly related. The data suggest numerous examples of lateral gene transfer, including a transfer from an alpha-proteobacterium to a plant. Glutathione synthetase sequences fall into two distinct groups: bacterial and eukaryotic. Proteins in both groups have a common structural fold, but the sequences are so divergent that it is uncertain whether these proteins are homologous or arose by convergent evolution.
        
        
          Conclusions
          The evolutionary history of the glutathione biosynthesis genes is more complex than anticipated. Our analysis suggests that the two genes in the pathway were acquired independently. The gene for γ-glutamylcysteine ligase most probably arose in cyanobacteria and was transferred to other bacteria, eukaryotes and at least one archaeon, although other scenarios cannot be ruled out. Because of high divergence in the sequences, the data neither support nor refute the hypothesis that the eukaryotic gene comes from a mitochondrial progenitor. After acquiring γ-glutamylcysteine ligase, eukaryotes and most bacteria apparently recruited a protein with the ATP-grasp superfamily structural fold to catalyze synthesis of glutathione from γ-glutamylcysteine and glycine. The eukaryotic glutathione synthetase did not evolve directly from the bacterial glutathione synthetase.
Percutaneous treatment of chronic MRSA osteomyelitis with a novel plant-derived antiseptic

Background
          Antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE, are an increasing problem world-wide, causing intractable wound infections. Complex phytochemical extracts such as tea tree oil and eucalypt-derived formulations have been shown to have strong bactericidal activity against MRSA in vitro. Polytoxinol (PT) antimicrobial, is the trade name of a range of antimicrobial preparations in solution, ointment and cream form.
        
        
          Methods
          We report the first use of this drug, administered percutaneously, via calcium sulphate pellets (Osteoset,TM), into bone, to treat an intractable MRSA infection of the lower tibia in an adult male.
        
        
          Results and Discussion
          Over a three month period his symptoms resolved with a healing response on x-ray and with a reduced CRP.
COVID-19 Estimated Patient Impact and Hospital Capacity by State

<p><b>Deprecated report</b>. This report was created early in the response to the COVID-19 pandemic. Increased reporting and quality in hospital data have rendered the estimated datasets obsolete. </p>

<p>The following dataset provides state-aggregated data for <b>estimated patient impact and hospital utilization</b>.</p>
<p>The source data for estimation is derived from reports with facility-level granularity across two main sources: (1) HHS TeleTracking, and (2) reporting provided directly to HHS Protect by state/territorial health departments on behalf of their healthcare facilities.</p>
<p>Estimates Basis: These files are representative estimates for each state and are updated weekly. These projections are based on the information we have from those who reported. As more hospitals report more frequently our projections become more accurate. The actual data for these data points are updated every day, once a day on healthdata.gov and these are the downloadable data sets.</p>
NNDSS - Table 1I. Cryptosporidiosis to Cyclosporiasis

NNDSS - Table 1I. Cryptosporidiosis to Cyclosporiasis - 2021. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notice: Due to data processing issues at CDC, data for the following jurisdictions may be incomplete for week 7: Alaska, Arizona, California, Connecticut, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Missouri, North Dakota, New Hampshire, New York City, Oregon, Pennsylvania, and Rhode Island.

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
 Max: Maximum — Maximum case count during the previous 52 weeks.
  * Case counts for reporting years 2020 and 2021 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
Respirable antisense oligonucleotides: a new drug class for respiratory disease

Respirable antisense oligonucleotides (RASONs), which attenuate specific disease-associated mRNAs, represent a new class of respiratory therapeutics with considerable potential. RASONs overcome previous obstacles that have impeded the development of antisense therapeutics targeting diseases in other organ systems. RASONs are delivered directly to the target tissue via inhalation; their uptake seems to be enhanced by cationic properties inherent in pulmonary surfactant, and, because of the markedly different target properties of mRNA and proteins, they can have very long durations of effect compared with traditional drugs targeting the protein of the same gene. RASONs contain chemical modifications that decrease their degradation by cellular nucleases. However, total insensitivity to nucleases is probably not an optimal design criterion for RASONs, because moderate nuclease sensitivity can prevent their systemic delivery, decreasing the potential for systemic toxicity. EPI-2010 is a 21-mer phosphorothioate RASON that attenuates bronchoconstriction, inflammation and surfactant depletion in preclinical models of human asthma, has a duration of effect of seven days, and seems to undergo minimal systemic delivery.
Patent AT-E401362-T1: [Translated] METHOD FOR SEPARATING A POLY(ARYLENE ETHER) FROM A SOLVENT

A method of separating a polymer-solvent mixture is described wherein a polymer-solvent mixture is heated prior to its introduction into an extruder comprising as upstream vent and/or a side feeder vent to allow flash evaporation of the solvent, and downstream vents for removal of remaining solvent. The one-step method is highly efficient having very high throughput rates while at the same time providing a polymer product containing low levels of residual solvent.
Modeling Neuroimmune Interactions in Human Subjects and Animal Models to Predict Subtype Specific Multidrug Treatments for Gulf War Illness

Gulf War Illness (GWI) is a persistent chronic neuroinflammatory illness exacerbated by external stressors and characterized by fatigue, musculoskeletal pain, cognitive and neurological problems linked to underlying immunological dysfunction for which there is no known treatment.  Here, we constructed a logic model of immune regulatory behavior between human clinical samples and mouse models of GWI subtyped by exposure to traumatic stress.  We identify several ideal multi-intervention strategies and potential drug candidates that may be used to treat chronic neuroinflammation in GWI.
Identification of sites phosphorylated by the vaccinia virus B1R kinase in viral protein H5R

Background
          Vaccinia virus gene B1R encodes a serine/threonine protein kinase. In vitro this protein kinase phosphorylates ribosomal proteins Sa and S2 and vaccinia virus protein H5R, proteins that become phosphorylated during infection. Nothing is known about the sites phosphorylated on these proteins or the general substrate specificity of the kinase. The work described is the first to address these questions.
        
        
          Results
          Vaccinia virus protein H5R was phosphorylated by the B1R protein kinase in vitro, digested with V8 protease, and phosphopeptides separated by HPLC. The N-terminal sequence of one radioactively labelled phosphopeptide was determined and found to correspond to residues 81-87 of the protein, with Thr-84 and Thr-85 being phosphorylated. A synthetic peptide based on this region of the protein was shown to be a substrate for the B1R protein kinase, and the extent of phosphorylation was substantially decreased if either Thr residue was replaced by an Ala.
        
        
          Conclusions
          We have identified the first phosphorylation site for the vaccinia virus B1R protein kinase. This gives important information about the substrate-specificity of the enzyme, which differs from that of other known protein kinases. It remains to be seen whether the same site is phosphorylated in vivo.
Program Instruction (PI-02-08)

This Program Instruction (PI) provides instruction on the Extension of Delayed Effective Date of Policy Regarding Title IV-E Administrative Costs for Children Placed in Unlicensed Foster Family Homes Issued in ACYF-CB-PA-01-02, "Clarifying Guidance Regarding Candidates for Foster Care," July 3, 2001.

Metadata-only record linking to the original dataset. Open original dataset below.
Itt1p, a novel protein inhibiting translation termination in

Background
          Termination of translation in eukaryotes is controlled by two interacting polypeptide chain release factors, eRFl and eRF3. eRFl recognizes nonsense codons UAA, UAG and UGA, while eRF3 stimulates polypeptide release from the ribosome in a GTP- and eRFl – dependent manner. Recent studies has shown that proteins interacting with these release factors can modulate the efficiency of nonsense codon readthrough.
        
        
          Results
          We have isolated a nonessential yeast gene, which causes suppression of nonsense mutations, being in a multicopy state. This gene encodes a protein designated Itt1p, possessing a zinc finger domain characteristic of the TRIAD proteins of higher eukaryotes. Overexpression of Itt1p decreases the efficiency of translation termination, resulting in the readthrough of all three types of nonsense codons. Itt1p interacts in vitro with both eRFl and eRF3. Overexpression of eRFl, but not of eRF3, abolishes the nonsense suppressor effect of overexpressed Itt1p.
        
        
          Conclusions
          The data obtained demonstrate that Itt1p can modulate the efficiency of translation termination in yeast. This protein possesses a zinc finger domain characteristic of the TRIAD proteins of higher eukaryotes, and this is a first observation of such protein being involved in translation.
4.16a Facility licensing, certification, or accreditation, by type of care offered: 2011. Number

This is a National Survey of Substance Abuse Treatment Services (N-SSATS) data table showing facility licensing, certification, or accreditation, by type of care offeredfacility in 2011. N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 States, the District of Columbia, and other U.S. jurisdictions.
Whole Genome Shotgun Submissions

Whole Genome Shotgun (WGS) projects are genome assemblies of incomplete genomes or incomplete chromosomes of prokaryotes or eukaryotes that are generally being sequenced by a whole genome shotgun strategy. WGS projects may be annotated, but annotation is not required. NCBI has a Prokaryotic Genomes Annotation Pipeline that may be requested at the time the genome files are submitted to GenBank. This pipeline generates a submission-ready annotated file that is posted back to the submitter for review and which the submitter could edit prior to data release.

The public WGS projects are at the list of WGS projects. https://www.ncbi.nlm.nih.gov/Traces/wgs/
Fluorescence of fungi in superficial and deep fungal infections

Background
          Fluorescence of many fungi is noted when H&E stained sections are examined under a fluorescent microscope. In theory, this phenomenon could aid in the diagnosis of cutaneous and disseminated fungal infections without the delay associated with special stains. Seventy-six cases of superficial and deep fungal infections and 3 cases of protothecosis were studied to determine the clinical usefulness of this technique.
        
        
          Results
          In most cases, fluorescence was noted, but was not intense. Fluorescence of fungi did not correlate with the age of the specimen. In most cases, organisms in H&E stained sections were more easily identified with routine light microscopy than with fluorescent microscopy.
        
        
          Conclusion
          This report suggests that in H&E stained skin specimens, fluorescent microscopy is of little benefit in the identification of fungal organisms.
Compound 526760: Prop-2-enyl 2-pentoxyacetate

Chemical compound data from PubChem database. IUPAC Name: prop-2-enyl 2-pentoxyacetate. Molecular Formula: C10H18O3. Molecular Weight: 186.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Public Service Loan Forgiveness Messaging Toolkit

Many of your staff, grant recipients and partners may be eligible for loan forgiveness.  Typically, to quality you must be employed by a U.S. federal, state, local, or tribal government, a 501(c)3 non-profit or a non-profit organization that provides a qualifying service (including military service).

You can tailor these resources to spread the word about the PSLF program.  Please consider sharing in your newsletters, social media feeds or at grant recipient convenings and conferences!

Subject:  Changes to Public Service Loan Forgiveness (PSLF) Program Offer More Options for Loan Forgiveness

[INSERT STATE] Employees May Now Be Eligible

The COVID-19 pandemic resulted in financial hardship for many, including members of the human services workforce. As a [INSERT STATE] employee, you may now be eligible for federal student loan forgiveness for your important public service, even if you were not eligible before.

ACF has created a PSLF landing page that includes resources for you to share.  It includes the March 31 webinar
  
  

 hosted by the Office of Early Childhood Development, in partnership with the Department of Education, attended by over 17,000 early educators. A webinar for the broader human services community was held on May 26th.  Both recordings, as well as PDFs and Frequently Asked Questions, are housed on the site. Please help us share this news with the broader human services workforce, including all of you who work here at [INSERT STATE].

The Department of Education issued a waiver that allows you to get credit for past payments even if you didn’t make the payment on time, didn’t pay the full amount due, or weren’t on a the right repayment plan. Until Oct. 31, 2022, federal student loan borrowers can get credit for payments that previously didn’t qualify for Public Service Loan Forgiveness (PSLF). Many people in the human services sector (including those that work in government and nonprofits) qualify for this program but don’t know about it. See if you qualify
  
  

.

Because of the COVID-19 emergency, the U.S. Department of Education announced a change to Public Service Loan Forgiveness (PSLF) program rules. For a limited time, borrowers may receive credit for past periods of repayment that would otherwise not qualify for loan forgiveness. The waiver expires October 31, 2022. See if you qualify and apply today
  
  

!

Did you know that for a limited time, borrowers may receive credit for past periods of repayment that would otherwise not qualify for the Public Service Loan Forgiveness program? Read the FAQs to learn more and see if you qualify.

Click to Retweet to Twitter

Click to Retweet to Twitter

Click to Retweet to Twitter

Metadata-only record linking to the original dataset. Open original dataset below.